miR-338在肿瘤中的研究进展  

Research progress of miR-338 in tumor

作　　者：何芳 秦青青 郑永钦[2] 贺军栋[1,2] HE Fang;QIN Qing-qing;ZHENG Yong-qin;HE Jun-dong(College of Medicine, Kunlning University of Science and Technology, Kunlning 650504;Institute of Clinical and Basic Medical Sciences,Yunnan Provincial First People＇s Hospital, Kunlning 650032, China)

机构地区：[1]昆明理工大学医学院,云南昆明650504 [2]云南省第一人民医院临床基础医学研究所,云南昆明650032

出　　处：《基础医学与临床》2018年第6期840-844,共5页Basic and Clinical Medicine

基　　金：国家自然科学基金(81360398;81660466);云南省卫生高层次人才项目(H-201642);云南省卫生科技计划项目(2016NS224)

摘　　要：microRNA(miRNA)是一类高度保守的内源性小型非编码调控核糖核酸,是肿瘤发生和发展的关键调节因子。miR-338在大多数肿瘤中异常表达,其异常表达能够影响肿瘤细胞的增殖、侵袭、转移和血管发生等生理活动,并通过靶向调控一个或多个靶基因发挥作用。MicroRNAs（ miRNAs） are a class of highly conserved,endogenous,small,non-coding RNAs that regulate RNAi and are key regulators of tumorigenesis and development. miR-338 is abnormally expressed in most tumors. Aberrant expression of miR-338 can affect the proliferation,invasion,metastasis,angiogenesis and other physiological activities of tumor cells and play a vital role in the regulation on one or more target-genes.

关 键 词：miR-338 肿瘤 

分 类 号：R73[医药卫生—肿瘤]